TESARO Issues Release Highlighting 'Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combo with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatment'
Benzinga Newsdesk